DK2001456T3 - Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser - Google Patents
Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelserInfo
- Publication number
- DK2001456T3 DK2001456T3 DK07727719.2T DK07727719T DK2001456T3 DK 2001456 T3 DK2001456 T3 DK 2001456T3 DK 07727719 T DK07727719 T DK 07727719T DK 2001456 T3 DK2001456 T3 DK 2001456T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- opioid receptor
- receptor antagonist
- kappa opioid
- containing compositions
- Prior art date
Links
- 208000018459 dissociative disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002618 kappa opiate receptor antagonist Substances 0.000 title 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract 1
- 108020001588 κ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| PCT/EP2007/053248 WO2007115975A2 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2001456T3 true DK2001456T3 (da) | 2010-04-12 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07727719.2T DK2001456T3 (da) | 2006-04-04 | 2007-04-03 | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (https=) |
| EP (1) | EP2001456B1 (https=) |
| JP (1) | JP5128578B2 (https=) |
| AT (1) | ATE450256T1 (https=) |
| AU (1) | AU2007236003B2 (https=) |
| CA (1) | CA2646899C (https=) |
| CY (1) | CY1109862T1 (https=) |
| DE (1) | DE502007002185D1 (https=) |
| DK (1) | DK2001456T3 (https=) |
| EA (1) | EA014820B1 (https=) |
| ES (1) | ES2337622T3 (https=) |
| HR (1) | HRP20100113T1 (https=) |
| PL (1) | PL2001456T3 (https=) |
| PT (1) | PT2001456E (https=) |
| RS (1) | RS51211B (https=) |
| SI (1) | SI2001456T1 (https=) |
| WO (1) | WO2007115975A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009094260A1 (en) | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| MX368870B (es) * | 2013-12-20 | 2019-10-21 | H Lundbeck As | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| PL3137081T3 (pl) | 2014-04-28 | 2018-06-29 | Orphomed, Inc. | Dimer buprenorfiny i jego zastosowanie w leczeniu chorób układu pokarmowego |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| EP4489730B1 (en) | 2022-03-07 | 2026-01-21 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| EP1061924A1 (en) * | 1998-03-09 | 2000-12-27 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| US20020045572A1 (en) * | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| AU2001275959A1 (en) | 2000-08-15 | 2002-02-25 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| JP2004518654A (ja) * | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| EP1613617A4 (en) * | 2003-04-04 | 2009-02-18 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| WO2005117910A2 (en) * | 2004-05-26 | 2005-12-15 | Inotek Pharmaceuticals Corporation | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
| ATE412404T1 (de) | 2004-06-02 | 2008-11-15 | Galephar M F | Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon |
-
2007
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 HR HR20100113T patent/HRP20100113T1/hr unknown
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de not_active Ceased
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20090181999A1 (en) | 2009-07-16 |
| EA200802104A1 (ru) | 2009-04-28 |
| WO2007115975A2 (de) | 2007-10-18 |
| PL2001456T3 (pl) | 2010-05-31 |
| EP2001456B1 (de) | 2009-12-02 |
| AU2007236003B2 (en) | 2012-10-18 |
| AU2007236003A1 (en) | 2007-10-18 |
| JP5128578B2 (ja) | 2013-01-23 |
| HRP20100113T1 (hr) | 2010-04-30 |
| US8063059B2 (en) | 2011-11-22 |
| SI2001456T1 (sl) | 2010-04-30 |
| CY1109862T1 (el) | 2014-09-10 |
| CA2646899C (en) | 2014-05-06 |
| EA014820B1 (ru) | 2011-02-28 |
| CA2646899A1 (en) | 2007-10-18 |
| RS51211B (sr) | 2010-12-31 |
| JP2009532434A (ja) | 2009-09-10 |
| ATE450256T1 (de) | 2009-12-15 |
| WO2007115975A3 (de) | 2008-02-14 |
| DE502007002185D1 (de) | 2010-01-14 |
| ES2337622T3 (es) | 2010-04-27 |
| EP2001456A2 (de) | 2008-12-17 |
| PT2001456E (pt) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10379A (es) | Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40. | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| CY1110882T1 (el) | Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης | |
| DE602007012072D1 (de) | Orantagonisten | |
| EP2170064A4 (en) | 6,5-pyrrolopiperidine tachykinin receptor antagonists | |
| DK2001456T3 (da) | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser | |
| IL208895A0 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| EP2150115A4 (en) | CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists | |
| DK2152690T3 (da) | Pyridylpiperidinorexin-receptorantagonister | |
| PT2570128T (pt) | Antagonistas do receptor muscarínico de acetilcolina | |
| EP2358371A4 (en) | P2X3 RECEPTOR ANTAGONISTS FOR PAIN TREATMENT | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| DK1729753T3 (da) | Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet | |
| ATE509928T1 (de) | 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten | |
| EP1765805A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
| EP2254413A4 (en) | IMIDAZOBENZAZEPIN-CGRP receptor antagonists | |
| SG163564A1 (en) | Kinin antagonists for treating bladder dysfunction | |
| DK1711465T3 (da) | Hydroisoindolin-tachykinikreceptorantagonister | |
| CL2007002611A1 (es) | Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad. | |
| DK1973886T3 (da) | Prokineticin-1-receptor-antagonister | |
| EP2075252A4 (en) | NK1 Receptor Antagonists COMPOSITION | |
| LT3456340T (lt) | Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui | |
| DK2091938T3 (da) | Piperidinylaminopyridaziner og anvendelse deraf som hurtigt opløsende antagonister af dopamin-2-receptorer | |
| EP1899318A4 (en) | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES | |
| EP2257534A4 (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |